CA3014776A1 - Pan-genotypic agents against influenza virus and methods of using the same - Google Patents

Pan-genotypic agents against influenza virus and methods of using the same Download PDF

Info

Publication number
CA3014776A1
CA3014776A1 CA3014776A CA3014776A CA3014776A1 CA 3014776 A1 CA3014776 A1 CA 3014776A1 CA 3014776 A CA3014776 A CA 3014776A CA 3014776 A CA3014776 A CA 3014776A CA 3014776 A1 CA3014776 A1 CA 3014776A1
Authority
CA
Canada
Prior art keywords
seq
lna
oligonucleotide
vrna
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3014776A
Other languages
English (en)
French (fr)
Inventor
Jeffrey S. Glenn
Rachel HAGEY
Edward Pham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA3014776A1 publication Critical patent/CA3014776A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3014776A 2016-03-02 2017-03-01 Pan-genotypic agents against influenza virus and methods of using the same Pending CA3014776A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302548P 2016-03-02 2016-03-02
US62/302,548 2016-03-02
PCT/US2017/020241 WO2017151795A1 (en) 2016-03-02 2017-03-01 Pan-genotypic agents against influenza virus and methods of using the same

Publications (1)

Publication Number Publication Date
CA3014776A1 true CA3014776A1 (en) 2017-09-08

Family

ID=59743201

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3014776A Pending CA3014776A1 (en) 2016-03-02 2017-03-01 Pan-genotypic agents against influenza virus and methods of using the same

Country Status (17)

Country Link
US (1) US10597658B2 (https=)
EP (3) EP3800257B1 (https=)
JP (3) JP7536272B2 (https=)
CN (1) CN108778344A (https=)
CA (1) CA3014776A1 (https=)
DK (1) DK3800257T3 (https=)
ES (1) ES2981765T3 (https=)
FI (1) FI3800257T3 (https=)
HR (1) HRP20240765T1 (https=)
HU (1) HUE066977T2 (https=)
LT (1) LT3800257T (https=)
PL (1) PL3800257T3 (https=)
PT (1) PT3800257T (https=)
RS (1) RS65707B1 (https=)
SI (1) SI3800257T1 (https=)
SM (1) SMT202400253T1 (https=)
WO (1) WO2017151795A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021201996A1 (en) * 2020-02-14 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against respiratory viruses and methods of using the same
US12522827B2 (en) 2016-03-02 2026-01-13 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
US11339392B2 (en) 2016-03-02 2022-05-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT69956A (en) * 1990-08-14 1995-09-28 Isis Pharmaceuticals Inc Methode for inhibition of influenza virus by antiseuse oligonucleotides
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US8357664B2 (en) * 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
AU2006235364A1 (en) * 2005-04-08 2006-10-19 Marina Biotech, Inc. RNAi therapeutic for respiratory virus infection
EP1937066A4 (en) * 2005-08-18 2008-12-24 Alnylam Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES
WO2007084359A2 (en) * 2006-01-17 2007-07-26 Oligos Etc., Inc. Compositions and methods for the treatment of influenza infection
CN100562342C (zh) * 2006-01-17 2009-11-25 奥林格斯技术有限公司 防治流感病毒感染的寡核苷酸药物
CA2666657A1 (en) * 2006-10-18 2008-04-24 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof
US20090042823A1 (en) 2007-08-10 2009-02-12 Mdrna, Inc. Uses of broad spectrum rnai therapeutics against influenza
CA2729757A1 (en) * 2008-07-01 2010-01-07 The Johns Hopkins University Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase
AU2009310557B2 (en) * 2008-10-27 2014-09-11 Academisch Ziekenhuis Leiden Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA
EP2499248B1 (en) 2009-11-13 2017-01-04 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
EP2519633B1 (en) * 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
CA2800281C (en) * 2010-06-01 2021-01-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases

Also Published As

Publication number Publication date
PL3800257T3 (pl) 2024-09-16
DK3800257T3 (da) 2024-06-24
HRP20240765T1 (hr) 2024-09-13
EP3423107A4 (en) 2020-01-15
JP2025096365A (ja) 2025-06-26
SMT202400253T1 (it) 2024-09-16
RS65707B1 (sr) 2024-08-30
US10597658B2 (en) 2020-03-24
JP2022176378A (ja) 2022-11-25
WO2017151795A1 (en) 2017-09-08
EP3800257A1 (en) 2021-04-07
EP4389221A3 (en) 2024-11-20
LT3800257T (lt) 2024-07-25
HUE066977T2 (hu) 2024-09-28
JP2019511471A (ja) 2019-04-25
EP4389221A2 (en) 2024-06-26
JP7536272B2 (ja) 2024-08-20
US20190136242A1 (en) 2019-05-09
ES2981765T3 (es) 2024-10-10
EP3423107A1 (en) 2019-01-09
PT3800257T (pt) 2024-06-26
EP3800257B1 (en) 2024-05-01
FI3800257T3 (fi) 2024-06-19
SI3800257T1 (sl) 2025-04-30
CN108778344A (zh) 2018-11-09

Similar Documents

Publication Publication Date Title
Steinhauer et al. Genetics of influenza viruses
Hutchinson et al. Genome packaging in influenza A virus
JP2025096365A (ja) インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法
Szabat et al. RNA secondary structure as a first step for rational design of the oligonucleotides towards inhibition of influenza a virus replication
WO2021201996A1 (en) Pan-genotypic agents against respiratory viruses and methods of using the same
Verity et al. Rapid generation of pandemic influenza virus vaccine candidate strains using synthetic DNA
US12522827B2 (en) Pan-genotypic agents against influenza virus and methods of using the same
Chiang et al. Mutations at alternative 5′ splice sites of M1 mRNA negatively affect influenza A virus viability and growth rate
US12618063B2 (en) Pan-genotypic agents against influenza virus and methods of using the same
US20240425852A1 (en) Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same
HK40113249A (en) Pan-genotypic agents against influenza virus and methods of using the same
Motard et al. A novel ribozyme-based prophylaxis inhibits influenza A virus replication and protects from severe disease
EP4464779A2 (en) Pan-genotypic agents against respiratory viruses and methods of using the same
HK40118855A (en) Pan-genotypic agents against respiratory viruses and methods of using the same
AU2024341512A1 (en) Agents against respiratory viruses and methods of using the same
US10383935B2 (en) Methods of making and using live attenuated viruses
Giannecchini et al. Packaging signals in the 5′-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules
HK40091735A (zh) 抗呼吸道病毒的泛基因型药剂及其使用方法
Hagey et al. Identification and targeting of a pan-genotypic influenza A virus RNA structure that mediates packaging and disease
HK1262033A1 (en) Pan-genotypic agents against influenza virus and methods of using the same
Winn The role of host factor Transportins in Influenza virus entry and infection
CN121001738A (zh) 流感病毒疫苗
WO2018140354A1 (en) Antisense oligonucleotides that inhibit influenza virus replication and uses thereof
Shen Study of influenza virus hemagglutinin

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220222

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240809

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250204

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250224

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250224

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250602

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250602

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251008